Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Sandia Akhtar |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Mortality among parkinson’s disease patients treated with pimavanserin or atypical antipsychotics / Andrew D. Mosholder en The American Journal of Psychiatry, Año 2022 - Vol. 179 - No. 8 (Agosto)
[artículo]
Título : Mortality among parkinson’s disease patients treated with pimavanserin or atypical antipsychotics : an observational study in medicare beneficiaries Tipo de documento: texto impreso Autores: Andrew D. Mosholder, Autor ; Yong Ma, Autor ; Sandia Akhtar, Autor Fecha de publicación: 2022 Artículo en la página: pp. 553-561 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Epidemiología, Neurología Resumen: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In premarketing trials in patients with Parkinson’s disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson’s disease psychosis, increase mortality in dementia patients. Link: ./index.php?lvl=notice_display&id=28626
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 8 (Agosto) . - pp. 553-561[artículo] Mortality among parkinson’s disease patients treated with pimavanserin or atypical antipsychotics : an observational study in medicare beneficiaries [texto impreso] / Andrew D. Mosholder, Autor ; Yong Ma, Autor ; Sandia Akhtar, Autor . - 2022 . - pp. 553-561.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 8 (Agosto) . - pp. 553-561
Palabras clave: Antipsicóticos, Epidemiología, Neurología Resumen: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In premarketing trials in patients with Parkinson’s disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson’s disease psychosis, increase mortality in dementia patients. Link: ./index.php?lvl=notice_display&id=28626